While such benefits should confer somecardiovascular benefit, the actions of agents of this class on the developmentand progression of atherosclerosis in diabetes remain to be established.However, some insight into the possible efficacy of pan PPAR agonists may beinferred from clinical studies using bezafibrate. The gene discussed is PPARA; the disease is atherosclerosis.